Abstract: Process for obtaining formic acid by thermal separation of a stream comprising formic acid and a tertiary amine (I), in which, in step (a), a liquid stream comprising formic acid, methanol, water and tertiary amine (I) is produced by combining methyl formate, water and tertiary amine (I), from there in step (b), methanol is separated off and in step (c), formic acid is removed by distillation from the liquid stream obtained in a distillation apparatus, wherein, when methyl formate, water and tertiary amine (I) are combined, methyl formate, water and optionally tertiary amine (I) are first introduced in step (a1) in a molar ratio of 0?n(amine to a1)/n(mefo to a1)?0.1, and from 70 to 100% of the hydrolysis equilibrium possible is set and then, in step (a2), tertiary amine (I) is introduced in a molar ratio of 0.1?n(amine to a2)/n(mefo to a1)?2, and the mixture is reacted.
Type:
Grant
Filed:
November 25, 2013
Date of Patent:
August 30, 2016
Assignee:
BASF SE
Inventors:
Donata Maria Fries, Klaus-Dieter Mohl, Martin Schäfer, Daniel Schneider, Peter Bassler, Stefan Rittinger, Joaquim Henrique Teles
Abstract: The present invention relates to a method of cleaving a ?-O-4 bond to the corresponding C—H bond in a substrate, by use of a hydrogen donor and a metal catalyst in a solvent. Thereby it is possible to depolymerize a polymer having a repeating ?-O-4 bond.
Type:
Grant
Filed:
September 9, 2013
Date of Patent:
August 23, 2016
Assignee:
KAT2BIZ AB
Inventors:
Joseph Samec, Maxim Galkin, Joakim Löfstedt
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Type:
Grant
Filed:
September 12, 2014
Date of Patent:
August 16, 2016
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander Rossi
Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.
Type:
Grant
Filed:
November 13, 2014
Date of Patent:
August 9, 2016
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: A method for production of a methionine salt in a reactive rectification column containing a weir having a height of 100 mm or more is provided.
Type:
Grant
Filed:
March 4, 2015
Date of Patent:
August 2, 2016
Assignee:
EVONIK DEGUSSA GmbH
Inventors:
Hans Joachim Hasselbach, Martin Koerfer, Christof P. Gruener, Franz H. Hanrath, Juergen Stock, Jignesh Gangadwala, Horst Krull
Abstract: The invention relates to a liquid-liquid extraction process, comprising: the provision of a main input liquid stream, comprising at least one compound of interest and an excess compound; the provision of a liquid scrubbing stream; the extraction of the excess compound from the main input liquid stream by contact with the liquid scrubbing stream, making it possible to collect a main output liquid stream, depleted in excess compound with respect to the main input liquid stream; in which: the main input liquid stream and the liquid scrubbing stream exhibit a difference in density of less than or equal to 50 kg/m3 and also an interfacial tension of less than or equal to 3 dyn/cm; and the extraction stage is carried out in a packed contactor with a ratio by weight as input liquid scrubbing stream/main liquid stream ranging from 0.3 to 0.5.
Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
Type:
Grant
Filed:
February 27, 2015
Date of Patent:
July 19, 2016
Assignee:
Receptos, Inc.
Inventors:
Esther Martinborough, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani
Abstract: A process for sulfonating at least one halobenzene with sulfur trioxide (SO3) comprising the following steps: Step 1. manufacturing a gaseous mixture [mixture (M)] comprising SO3 and at least one additional gas different from SO3 by oxidizing sulfur dioxide in the presence of at least one catalyst, wherein the SO3 content in mixture (M) is from 1 to 95% by volume, relative to the total volume of mixture (M); and step 2 contacting said mixture (M) with said at least one halobenzene.
Type:
Grant
Filed:
August 13, 2013
Date of Patent:
July 19, 2016
Assignee:
SOLVAY SPECIALTY POLYMERS USA, LLC.
Inventors:
Mahendra Dosi, Ziad Husein, Ronald Mysona
Abstract: The present invention relates to a method for preparing an aqueous sulfonimide compound of the formula (Rf1—SO2)(Rf2—SO2)NH, wherein Rf1 and Rf2 are independently selected from the group comprising: a fluorine atom and groups having 1 to 10 carbon atoms selected from the perfluoroalkyl, fluoroalkyl, fluoroalkenyl and fluoroallyl groups, from a mixture M1 including (Rf1—SO2)(Rf2—SO2)NH, Rf1SO2H and/or Rf2SO2H, Rf1SO2NH2 and/or Rf2SO2NH2, characterized in that said method includes an oxidation step of said mixture M1 using an oxidizing agent in order to obtain a mixture M2 including (Rf1—SO2)(Rf2—SO2)NH, Rf1SO3H and/or Rf2SO3H and Rf1SO2NH2and/or Rf2SO2NH2.
Type:
Grant
Filed:
July 11, 2013
Date of Patent:
July 19, 2016
Assignee:
RHODIA OPERATIONS
Inventors:
Bernard Besson, Francois Metz, Olivier Buisine
Abstract: A method for manufacturing a water resistant optically anisotropic film capable of suppressing the generation of a defect such as a crack or separation is provided. The method for manufacturing the water resistant optically anisotropic of the present invention includes a water resistant treatment step of bringing an optically anisotropic film containing an organic dye having an anionic group into contact with a water resistant treatment liquid containing a multivalent cationic compound and a monovalent cationic compound, and the mass ratio of the multivalent cationic compound and the monovalent cationic compound contained in the water resistant treatment liquid, monovalent cationic compound/multivalent cationic compound, is 0.01 to 2.
Abstract: The object of the present invention is to provide a process for producing ?-fluoroacrylic acid ester at a high starting material conversion, high selectivity, and high yield. The present invention provides a process for producing the compound represented by the formula (1) wherein R represents alkyl optionally substituted with one or more fluorine atoms, the process comprising step A of reacting a compound represented by the formula (2) wherein X represents a bromine atom or a chlorine atom with an alcohol represented by the formula (3) wherein the symbol is as defined above, and carbon monoxide in the presence of a transition metal catalyst and a base to thereby obtain the compound represented by the formula (1).
Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
July 12, 2016
Assignee:
Celgene International II Sárl
Inventors:
Esther Martinborough, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani, Gregg Alan Timony, Jennifer L. Brooks, Robert Peach, Fiona Lorraine Scott, Michael Allen Hanson
Abstract: Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder.
Type:
Grant
Filed:
April 30, 2013
Date of Patent:
July 12, 2016
Assignee:
Allergan, Inc.
Inventors:
Julie Himes, Dennis Giesing, Cheryl Larrivee-Elkins, Michael J. Cima, Purnanand Sarma, Paul Goldenheim
Abstract: The present invention relates to a device for treatment of material transported through the device comprising at least one porous element consisting of specific solid metallic structure which allows cross-flow of the material through the porous element and wherein the porous element is coated by a non-acidic metal oxide which is impregnated by palladium (Pd).
Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Abstract: The present invention provides novel polymerizable monomers having chelating functionality and processes to make them. In particular, the novel monomers are ethylenically unsaturated aminocarboxylates and are prepared by reacting ethylenediamine triacetic acid or its salt with an ethylenically unsaturated monomer. The ethyleneically unsaturated monomer may be a polymerizable vinyl monomer selected from (o-, p-, m-)DVBMO, allyl glycidyl ether, and glycidyl (meth)acrylate.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
June 28, 2016
Inventors:
Scott Backer, Allen Bulick, Joseph Manna, Cynthia Rand, Jia Xie
Abstract: Provided is a method for industrially producing a conjugated Z-alken-yn-yl acetate such as Z-13-hexadecen-11-yn-yl acetate which is a sex pheromone component of a pine processionary moth, and an intermediate for the conjugated Z-alken-yn-yl acetate under mild conditions at a high yield. More specifically, provided is a method for producing a conjugated Z-alken-yn-yl acetate (5) comprising the steps of: reacting an ?-halo-2-alkynal (1) with an alkylidene triphenylphosphorane (3) through a Wittig reaction to obtain a conjugated Z-alken-yn-yl halide (4), and acetoxylating the conjugated Z-alken-yn-yl halide (4) into a conjugated Z-alken-yn-yl acetate (5).
Abstract: Disclosed herein inter alia are Boron containing compounds and methods for treating infections related to antibiotic resistant microorganisms.
Type:
Grant
Filed:
April 14, 2014
Date of Patent:
June 21, 2016
Assignees:
The Regents of the University of California, Universita' degli Studi di Modena e Reggio Emilia
Inventors:
Brian K. Shoichet, Fabio Prati, Emilia Caselli, Chiara Romagnoli, Oliv Eidam
Abstract: In production of a cationic lipid having at least one methylene group sandwiched between adjacent two cis form double bonds in the molecule, isomerization from a cis form to a trans form is suppressed. A compound represented by the following formula (I): R1—X??(I) (in Formula, R1 represents a hydrocarbon group having at least one methylene group sandwiched between adjacent two cis form double bonds in the molecule and having the carbon number of 8 to 24 and X represents a releasing group) is reacted with (B) a compound having at least one of each of tertiary amino group and hydroxyl group in the molecule in a saturated hydrocarbon solvent having the carbon number of 5 to 10 in the presence of an alkali catalyst.